查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
传染病诊断测试的全球市场
市场调查报告书
商品编码
1069070

传染病诊断测试的全球市场

Infectious Disease Diagnostic Testing: World Market Analysis
出版日期: | 出版商: Kalorama Information | 英文 264 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录
本报告调查了全球传染病诊断检测市场，并提供了市场概况，以及产品趋势、区域趋势和进入市场的公司概况。

目录

第 1 章执行摘要

第二章市场环境

  • 概览
  • 人口
  • 年龄分布
  • 宏观经济环境
  • 全球经济展望
  • 人均国内生产总值
  • 全球医疗保健趋势
  • 传染病病例
  • 医疗保健提供者
  • 患者活动
  • 住院
  • 住院时间
  • 外科手术
  • 门诊咨询
  • 体外诊断测试

第三章传染病体外诊断产品和市场

  • 概览
  • 性传播疾病 (STI)
  • 沙眼衣原体(Chlamydia)
  • 人乳头瘤病毒（HPV）
  • 淋病
  • 单纯疱疹病毒2（HSV-2）
  • 梅毒
  • 其他性传播疾病 (STD) 体外诊断产品
  • 医疗相关传染病
  • 艰难梭菌 (C. diff)
  • 败血症
  • 耐甲氧西林金黄色葡萄球菌（MRSA）
  • 耐万古霉素肠球菌（VRE）
  • 其他 HAI
  • 鑑定和抗生素药敏试验 (ID/AST) 产品
  • 自动识别/AST 产品
  • 手动面板和试剂
  • 製片人
  • IVD肝炎产品
  • HIV/AIDS IVD产品
  • 流感
  • 结核病 (TB)
  • 火炬
  • 所有其他传染病IVD产品
  • 新冠肺炎 (COVID-19)
  • 世界传染病IVD技术
  • 免疫学检查
  • 分子技术
  • 传统微生物学
  • 按市场分列的全球传染病 IVD 需求

第 4 章世界市场

  • 概览
  • 北美
  • 美国
  • 加拿大
  • 墨西哥
  • 西欧
  • 德国
  • 法国
  • 英国
  • 意大利
  • 西班牙
  • 其他西欧国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太国家
  • 其他领域
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 哥伦比亚
  • 秘鲁
  • 智利
  • 非洲/中东
  • 土耳其
  • 沙特阿拉伯
  • 伊朗
  • 埃及
  • 伊拉克
  • 尼日利亚
  • 南非
  • 以色列
  • 阿拉伯联合酋长国
  • 所有其他国家和地区

第 5 章公司简介

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • bioM?rieux
  • Bruker Corporation
  • Danaher Corporation
  • DiaSorin
  • Grifols S.A.
  • Hologic
  • Ortho Clinical Diagnostics Holdings
  • QIAGEN
  • Quidel Corporation
  • Roche Holding
  • Siemens Healthineers
  • Thermo Fisher Scientific
简介目录
Product Code: 22-022

Infectious disease testing comprises one of the largest and fastest growing applications served by the global in vitro diagnostics (IVD) industry. Infectious diseases are ailments caused by pathogenic microorganisms that invade the body, either directly or indirectly via afflicted carriers or contaminated sources. IVD tests for these conditions are designed to detect and identify the responsible pathogen, pinpoint its origin, and determine an appropriate antimicrobial therapy.

Infectious disease IVD products include reagents, consumables, and instruments based primarily on immunoassays, molecular technologies, and conventional microbiology techniques. Specific types of tests are available for detecting hundreds of pathogenic conditions. The report examines the global demand for infectious disease IVD products, which is projected to increase as medical providers and healthcare organizations throughout the world heighten efforts to combat proliferating epidemic threats.

This report, “Infectious Disease Diagnostic Testing: World Market Analysis”, examines the global market for infectious disease testing products. Specific applications analyzed include:

  • Healthcare-associated and opportunistic infections
  • Antimicrobial-resistant pathogens including bacteria, fungi, parasites, and viruses
  • Human immunodeficiency virus (HIV) and hepatitis viruses
  • Diseases related to women's health and sexually transmitted infections (STDs)
  • Emerging, neglected, and tropical disease threats
  • Respiratory tract infections and respiratory viruses (including COVID-19)

Geographic and Country Markets

Opportunities for infectious disease testing products vary widely between the developed and developing countries. Regions covered include:

  • North America
  • Eastern Europe
  • Western Europe
  • Asia/Pacific
  • Africa/Middle East
  • Central and South America
  • Other Regions

Market Drivers

The report examines market drivers, including external market influences that are promoting the development and use of improved infectious disease diagnostics. Public health officials worldwide have begun to recognize the global nature of infectious diseases - they are no longer solely a problem of developing countries but touch the very fabric of the social and economic welfare of countries in the industrialized world as well. Over the long term, aging populations and problems posed by infectious diseases will strain healthcare resources in many countries.

Competitive Landscape

The report details the major competitors that are global market leaders in infectious disease testing products and technologies, including an overview and an outline of these company's infectious disease IVD products:

  • Abbott Laboratories
  • Becton, Dickinson and Company (BD)
  • bioMérieux Inc.
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • DiaSorin S.p.A.
  • Grifols
  • Hologic, Inc.
  • Ortho-Clinical Diagnostics
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche
  • Siemens AG
  • Thermo Fisher Scientific Inc.

The information presented herein is derived from publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and selected direct interviews with industry experts conducted previously.

Estimates in the report are based on an examination of epidemiological statistics, test pricing, annual reports of key competitors and regional sales, as well as Kalorama Information's databases and economic composites. Forecasts presented for Eastern Europe were prepared prior to Russia's invasion of Ukraine and its negative impact on the healthcare systems of both countries.

Table of Contents

Chapter 1: Executive Summary

  • A Mix of Traditional and Emerging Testing Technologies
  • Market Drivers
  • The World Infectious Disease Testing Market
    • Table 1-1a: World Infectious Disease Diagnostic Test Market, 2018-2026 ($ millions)
    • Table 1-1b: World Infectious Disease Diagnostic Test Market, 2027-2031 ($ millions)
  • Major Findings of the Report
    • Table 1-2: Selected Infectious Diseases, Global Incidence, Prevalence, & Mortality, 2021
  • Scope and Methodology

Chapter 2: Market Environment

  • Overview
  • Population
    • Table 2-1a: Population by Country, 2018-2025 (million)
    • Table 2-1b: Population by Country, 2026-2031 (million)
  • Age Distribution
    • Table 2-2a: Population 50 Years & Older by Country, 2018-2025 (million)
    • Table 2-2b: Population 50 Years & Older by Country, 2026-2031 (million)
    • Table 2-3a: Population 65 Years & Older by Country, 2018-2025 (million)
    • Table 2-3b: Population 65 Years & Older by Country, 2026-2031 (million)
  • Macroeconomic Environment
  • Global Economic Outlook
    • Table 2-4a: Gross Domestic Product by Country, 2018-2025 (billion dollars)
    • Table 2-4b: Gross Domestic Product by Country, 2026-2031 (billion dollars)
  • Per Capita Gross Domestic Product
    • Table 2-5a: Per Capita Gross Domestic Product by Country, 2018-2025 (dollars)
    • Table 2-5b: Per Capita Gross Domestic Product by Country, 2026-2031 (dollars)
  • Global Healthcare Trends
  • Infectious Disease Cases
    • Table 2-6a: Number of Infectious Disease Cases by Country, 2018-2025 (million)
    • Table 2-6b: Number of Infectious Disease Cases by Country, 2026-2031 (million)
    • Table 2-7a: Health Expenditures by Country, 2018-2025 (billion dollars)
    • Table 2-7b: Health Expenditures by Country, 2026-2031 (billion dollars)
  • Medical Providers
    • Table 2-8 Medical Providers, Selected Countries, 2021
  • Patient Activity
  • Hospital Admissions
    • Table 2-9a: Hospital Admissions by Country, 2018-2025 (million)
    • Table 2-9b.: Hospital Admissions by Country, 2026-2031 (million)
  • Inpatient Days
    • Table 2-10a: Inpatient Days by Country, 2018-2025 (million)
    • Table 2-10b: Inpatient Days by Country, 2026-2031 (million)
  • Surgical Procedures
    • Table 2-11a: Surgical Procedures by Country, 2018-2025 (million)
    • Table 2-11b: Surgical Procedures by Country, 2026-2031 (million)
  • Outpatient Consultations
    • Table 2-12a: Outpatient Consultations by Country, 2018-2025 (million)
    • Table 2-12b: Outpatient Consultations by Country, 2026-2031 (million)
  • IVD Tests
    • Table 2-13a: IVD Tests by Country, 2018-2025 (million)
    • Table 2-13b: IVD Tests by Country, 2026-2031 (million)

Chapter 3: Infectious Disease IVD Products & Markets

  • Overview
    • Table 3-1a: Global Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 3-1b: Global Infectious Disease IVD Products Demand by Type, 2026-2031 (million dollars)
  • Sexually Transmitted Infections (STIs)
    • Table 3-2a: Global Sexually Transmitted Infection IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-2b: Global Sexually Transmitted Infections IVD Products Demand, 2026-2031 (million dollars)
  • Chlamydia Trachomatis (chlamydia)
  • Human Papillomavirus (HPV)
  • Gonorrhea
  • Herpes Simplex Virus 2 (HSV-2)
  • Syphilis
  • Other Sexually Transmitted Disease (STD) IVD Products
  • Healthcare-Associated Infections
    • Table 3-3a: Global Healthcare-Associated Infection IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-3b: Global Healthcare-Associated Infections IVD Products Demand, 2026-2031 (million dollars)
  • Clostridium difficile (C. diff)
  • Sepsis
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Vancomycin-Resistant Enterococcus (VRE)
  • Other HAIs
  • Identification & Antibiotic Susceptibility Testing (ID/AST) Products
    • Table 3-4a: Global ID/AST IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-4b: Global ID/AST IVD Products Demand, 2026-2031 (million dollars)
  • Automated ID/AST Products
  • Manual Panels & Reagents
  • Producers
  • Hepatitis IVD Products
    • Table 3-5a: Global Hepatitis IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-5b: Global Hepatitis IVD Products Demand, 2026-2031 (million dollars)
  • HIV/AIDS IVD Products
    • Table 3-6a: Global HIV/AIDS IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-6b: Global HIV/AIDS IVD Products Demand, 2026-2031 (million dollars)
  • Influenza
    • Table 3-7a: Global Influenza IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-7b: Global Influenza IVD Products Demand, 2026-2031 (million dollars)
  • Tuberculosis (TB)
    • Table 3-8a: Global Tuberculosis IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-8b: Global Tuberculosis IVD Products Demand, 2026-2031 (million dollars)
  • TORCH
    • Table 3-9a: Global TORCH IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-9b: Global TORCH IVD Products Demand, 2026-2031 (million dollars)
  • All Other Infectious Disease IVD Products
    • Table 3-10a: Global Other Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-10b: Global Other Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Malaria
  • Streptococcal Infections
  • Fungal Infections
  • Parasitic Conditions
  • Lyme Disease
  • Respiratory Syncytial Virus (RSV)
  • Emerging Infections
  • Chikungunya
  • Dengue Fever
  • Additional Products
  • COVID-19
    • Table 3-11 Global COVID-19 IVD Products Demand, 2018-2026 (million dollars)
  • Global Infectious Disease IVD Technologies
    • Table 3-12a: Global Infectious Disease IVD Products Demand by Technology, 2018-2025 (million dollars)
    • Table 3-12b: Global Infectious Disease IVD Products Demand by Technology, 2026-2031 (million dollars)
  • Immunoassays
    • Table 3-13a: Global Immunoassay Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-13b: Global Immunoassay Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Molecular Technologies
    • Table 3-14a: Global Molecular Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-14b: Global Molecular Infectious Disease IVD Products Demand 2026-2031 (million dollars)
  • Conventional Microbiology
    • Table 3-15a: Global Microbiology Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-15b: Global Microbiology Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Global Infectious Disease IVD Demand by Market
    • Table 3-16a: Global Infectious Disease IVD Products Demand by Site, 2018-2025 (million dollars)
    • Table 3-16b: Global Infectious Disease IVD Products Demand by Site, 2026-2031 (million dollars)
    • Table 3-17a: Global Laboratory Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-17b: Global Laboratory Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
    • Table 3-18a: Global Point-of-Care Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 3-18b: Global Point-of-Care Infectious Disease IVD Products Demand, 2026-2031 (million dollars)

Chapter 4: Global Markets

  • Overview
    • Table 4-1a: Infectious Disease IVD Products Demand by Country, 2018-2025 (million dollars)
    • Table 4-1b: Infectious Disease IVD Products Demand by Country/Region, 2026-2031 (million dollars)
  • North America
    • Table 4-2a: North America: Infectious Disease IVD Products Demand, 2018-2025 (million dollars)
    • Table 4-2b: North America: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • United States
    • Table 4-3a: United States: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-3b: United States: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Canada
    • Table 4-4a: Canada: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-4b: Canada: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Mexico
    • Table 4-5a: Mexico: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-5b: Mexico: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Western Europe
    • Table 4-6a: Western Europe: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-6b: Western Europe: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Germany
    • Table 4-7a: Germany: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-7b: Germany: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • France
    • Table 4-8a: France: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-8b: France: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • United Kingdom
    • Table 4-9a: United Kingdom: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-9b: United Kingdom: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Italy
    • Table 4-10a: Italy: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-10b: Italy: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Spain
    • Table 4-11a: Spain: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-11b: Spain: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Other Western Europe
    • Table 4-12a: Other Western Europe: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-12b: Other Western Europe: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Netherlands
  • Belgium
  • Sweden
  • Austria
  • Switzerland
  • Norway
  • Denmark
  • Portugal
  • Ireland
  • Greece
  • Finland
  • All Other Countries & Territories
  • Asia/Pacific
    • Table 4-13a: Asia/Pacific: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-13b: Asia/Pacific: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • China
    • Table 4-14a: China: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-14b: China: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • India
    • Table 4-15a: India: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-15b: India: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Japan
    • Table 4-16a: Japan: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-16b: Japan: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • South Korea
    • Table 4-17a: South Korea: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-17b: South Korea: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Other Asia/Pacific
    • Table 4-18a: Other Asia/Pacific: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-18b: Other Asia/Pacific: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Indonesia
  • Australia
  • Philippines
  • Thailand
  • Taiwan
  • Vietnam
  • Malaysia
  • Pakistan
  • Hong Kong
  • Singapore
  • New Zealand
  • All Other Countries & Territories
  • Other Regions
    • Table 4-19a: Other Regions: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-19b: Other Regions: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Central & South America
    • Table 4-20a: Central & South America: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-20b: Central & South America: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Brazil
  • Argentina
  • Colombia
  • Peru
  • Chile
  • All Other Countries & Territories
  • Eastern Europe
    • Table 4-21a: Eastern Europe: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-21b: Eastern Europe: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Russia
  • Poland
  • Romania
  • Czech Republic
  • Hungary
  • All Other Countries
  • Africa/Middle East
    • Table 4-22a: Africa/Middle East: Infectious Disease IVD Products Demand by Type, 2018-2025 (million dollars)
    • Table 4-22b: Africa/Middle East: Infectious Disease IVD Products Demand, 2026-2031 (million dollars)
  • Turkey
  • Saudi Arabia
  • Iran
  • Egypt
  • Iraq
  • Nigeria
  • South Africa
  • Israel
  • United Arab Emirates
  • All Other Countries & Territories

Chapter 5: Company Profiles

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • bioMérieux
  • Bruker Corporation
  • Danaher Corporation
  • DiaSorin
  • Grifols S.A.
  • Hologic
  • Ortho Clinical Diagnostics Holdings
  • QIAGEN
  • Quidel Corporation
  • Roche Holding
  • Immunoassays
  • COVID-19
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Microbiology
  • COVID-19